argenx clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
12 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 8 with minor changes only.
- Notable: ADAPT-EARLY · Outcomes of Efgartigimod PH20 SC · New-onset Generalized Myasthenia Gravis (gMG) Primary endpoint(s) modified
- Notable: SERENITY · Efgartigimod · Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy Recruitment opened
- Minor: Sparkle · Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy Trial sites expanded: 28 → 46 locations
- Minor: ADAPT Forward2 · ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 14 → 19 locations
- Stopped: Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Withdrawn before enrolling
- Minor: Empasiprubart · CIDP Trial sites expanded: 89 → 94 locations
- Minor: Natural History Study · Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 Enrollment closed, study ongoing
- Minor: Empasiprubart Versus IVIg · CIDP Trial sites expanded: 101 → 107 locations
- Minor: VitaliThy · Efgartigimod PH20 SC PFS · Graves' Disease Trial sites expanded: 32 → 35 locations
- Minor: VitaliThy · Efgartigimod PH20 SC PFS · Graves' Disease Trial sites expanded: 42 → 51 locations
- Minor: ADAPT Jr · Efgartigimod Administered Intravenously · Generalized Myasthenia Gravis Enrollment closed, study ongoing
- Notable: Verdant · ARGX-121 on the Change in Proteinuria · IgAN Recruitment opened
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 5 | |
| Phase 2 | 13 | |
| Phase 2/3 | 4 | |
| Phase 3 | 12 | |
| Phase 4 | 1 |
Not charted: 7 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials
Myasthenia Gravis (12) · Scleroderma (1) · Spinal Muscular Atrophy (1)
Get alerts when argenx's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.